Xu Zhu

Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches

A. Chaudhury, C. June, A. Stein, 2020, Journal of clinical pharmacology.

Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial

W. Jusko, W. Krzyzanski, Tianjing Ren, 2022, Journal of Pharmacokinetics and Pharmacodynamics.

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

B. Tran, N. Concin, Y. Ando, 2021, Oncology Research and Treatment.

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

J. Briones, I. Flinn, U. Jaeger, 2021, Blood.

Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy

Jennifer Yang, B. Engels, J. Brogdon, 2021, Blood.

Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma

Carla P. Guimarães, J. Brogdon, Poonam Vaidya, 2021, Blood.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

J. Briones, I. Flinn, D. Blaise, 2023, Cancer discovery.